Lung Cancer - Multimodality Therapy

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors do not report synergic side...

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors...

JANS Article

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer

November 9, 2023 | Javeria Tariq

This paper looked at the immunotherapy agent Durvalumab used in the perioperative period for resectable NSCLC. A total of 802 patients were enrolled in the study, of which 400 received...

JANS Article

The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and Multidisciplinary Management of Patients with Early-Stage Non-Small Cell Lung Cancer

June 15, 2023 | Cameron LindSilver Contributor

A new expert consensus on diagnosis, staging, and therapy for early-stage non-small cell lung cancer patients has been released. The experts recommend CT and PET imaging as a necessary part...

JANS Article

NIH Grant Funds Cancer Prevention Vaccine Research

December 9, 2022 | Cameron LindSilver Contributor

Researchers have been awarded a grant to fund cancer vaccine research, including the development of an mRNA vaccine that would target precancerous lung lesions. Eventually, researchers hope to develop an...

JANS Article

Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer

March 4, 2019 | Marco NardiniBronze Contributor

The complete pathologic response rate in this study is revealed to be low, lower than expected after stereotactic ablative radiotherapy (SABR) for early stage non-small cell lung cancer: only 60%....

JANS Article

Aggressive Radiotherapy, Surgery Doubles Overall Survival in Non-Small Cell Lung Cancer With Limited Mets

October 23, 2018 | Mark FergusonBronze Contributor

Forty-nine patients with limited metastatic non-small cell lung cancer (three or fewer metastatic sites) who did not progress on initial systemic therapy were randomized to surgery or RT vs standard...

JANS Article

Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC

September 25, 2018 | Mark FergusonBronze Contributor

This comprises the eagerly anticipated summary of the second primary endpoint of the PACIFIC trial of Durvalumab vs placebo in patients who completed CT/RT without progression for unresectable stage III...

JANS Article

PACIFIC: Time for a Surgical IIIA Uprising

August 20, 2018 | Mark FergusonBronze Contributor

This provocative editorial outlines concepts that thoracic surgeons should understand in the era of immunotherapy for potentially resectable N2 disease.

...
Video

Making Difficult Decisions in Lung Cancer: Oligometastasis, Ground Glass Opacities, Bilateral Lung Lesions, Surgery for Recurrence

July 5, 2018 | Gilbert Massard

Gilbert Massard of the Centre Hospitalier in Strasbourg, France, discusses difficult treatment decisions in lung cancer. He reviews the different treatment approaches for oligometastasis, ground glass opacities, and multiple primary...

JANS Article

Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base

April 13, 2018 | Mark FergusonBronze Contributor

The authors found that adjuvent chemoradiotherapy after resection of N2 NSCLC was more effective if given sequentially than concomitantly.

...
JANS Article

Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

February 5, 2018 | Mark FergusonBronze Contributor

This randomized trial compared chemoradiotherapy alone to chemoradiotherapy followed by consolidation therapy with the PDL-1 antibody durvalumab in patients with stage III NSCLC. The treatment group had significantly improved progression-free...

JANS Article

Lung Cancer Awareness Month—A Lot of Progress, But More Work Needs to Be Done

October 24, 2017 | Mark FergusonBronze Contributor

A useful reminder of the substantial progress that has been made and the continuing challenges that we face in fighting this terrible disease.

...
LOAD MORE
ADVERTISE ON CTSNET